Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509280 | 0.74 | KCNH2 (0.41) | — | |
| SCHEMBL24533836 | 0.73 | HDAC6 (0.48) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL2224130 | 0.71 | HDAC4 (0.47) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL1347465 | 0.69 | HDAC6 (0.36) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL16085909 | 0.65 | NR1I2 (0.59) | HDAC6HDAC1HDAC8HDAC4HDAC5 | |
| SCHEMBL4733455 | 0.62 | CYP19A1 (0.53) | — | |
| SCHEMBL4181312 | 0.62 | GRM5 (0.60) | GRM5S1PR1S1PR5 | |
| SCHEMBL18824381 | 0.61 | HDAC4 (0.66) | HDAC6HDAC1HDAC8HDAC4 | |
| SCHEMBL21255718 | 0.61 | S1PR1 (0.69) | HDAC6HDAC1HDAC8HDAC5S1PR1 | |
| SCHEMBL2226598 | 0.61 | HDAC4 (0.48) | HDAC6HDAC1HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | HDAC6 3717/4885HDAC1 1786/4885HDAC8 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.